Perseus Proteomics Inc.
HOMECorporate ProfileResearch & DevelopmentProduct InformationContract Service
Corporate Profile

Corporate Infomation

Perseus Proteomics Inc. [as of 21 Jun. 2018]

Company name Perseus Proteomics Inc.

Corporate headquarters
4-7-6, Komaba Meguro-ku, Tokyo 153-0041, JAPAN
Telephone : +81-3-5738-1705
FAX : +81-3-3481-5760

Established February 1, 2001

Capital 800 million Yen

Number of employees 20

Board of Directors

President & CEO Takuya Yokokawa

Director Takao Hamakubo, Professor, M.D.,Ph.D. (NIPPON MEDICAL SCHOOL)

Toshikazu Ban (FUJIFILM Corporation, Corporate Vice President)

Minoru Tagaya (Nippon Venture Capital Co.,Ltd. Director Managing Executive Officer)

Kinichiro Kominami (Tech & FinStrategy, Inc. President & CEO)

Statutory Auditors

Hirokazu Asami

Corporate History

February, 2001 Founded as a biotech venture company using technology developed at the Laboratory for System Biology and Medicine (LSBM), a division of the Research Center for Advanced Science and Technology (RCAST) at the University of Tokyo.

October, 2002 Established a research and development laboratory at Komaba, Meguro-ku, Tokyo.

April, 2003 Participated in government sponsored national project entitled "Bionanochip for the Analysis of Protein Interactions" (project leader: Dr. Tatsuhiko Kodama), administered by the New Energy and Industrial Technology Development Organization (NEDO).

May, 2004 Establishment of a joint partnership with CMIC Co., Ltd (Tokyo, Japan) for the development and production of diagnostic kits targeting PTX3, a promising biomarker for arteriosclerosis.

August, 2004 Signed an agreement with R&D Systems Inc. (Minnesota, USA) for the sale and distribution of Perseus Proteomics nuclear receptor monoclonal antibodies

January, 2006 Raised $9.5m (1.1 billion yen) from Fuji Photo Film Co., Ltd., IRI Finance and Technology, Inc., a subsidiary of Internet Research Institute, Inc., and venture capital.

September, 2008 PPMX's anti-GPC3 antibody entered into clinical trial in the USA.

January, 2009 PPMX received one billion yen from FUJIFILM in a third-party allocation of shares, and became a subsidiary company of FUJIFILM.

December,2014 PPMX receives JST Grant to develop Anti TfR antibody for Adult T-cell Leukemia.

January,2016 Fujifilm initiates a Phase I clinical trial of the anti-cancer agent "FF-21101" (RI labeled antibody) in the United States. PPMX contributed to creating antibody based on antibody engineering technology.

March, 2018 PPMX received 1.4 billion yen from Nippon Venture Capital Co.,Ltd. and other capitals in a third party allocation of shares.